- Report
- November 2022
- 89 Pages
Europe
From €1432EUR$1,500USD£1,199GBP
- Report
- August 2022
United States
From €1851EUR$1,940USD£1,551GBP
- Report
- August 2022
Global
From €754EUR$790USD£632GBP
- Report
- December 2023
- 275 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- September 2024
- 87 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2022
- 84 Pages
Global
From €3200EUR$3,592USD£2,775GBP
- Report
- January 2022
- 92 Pages
Global
From €3200EUR$3,592USD£2,775GBP
- Report
- May 2022
- 68 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
Actinic Keratosis (AK) is a pre-cancerous skin condition caused by long-term exposure to ultraviolet (UV) radiation. It is characterized by scaly, rough patches on the skin that can become cancerous if left untreated. Skin cancer drugs are used to treat AK and prevent it from progressing to a more serious form of skin cancer. These drugs are typically topical creams or ointments that are applied directly to the affected area. They work by slowing down the growth of abnormal cells and preventing them from spreading.
The Actinic Keratosis Drug market is a subset of the larger Skin Cancer Drug market. It is composed of a variety of products, including topical creams, ointments, and other treatments. These products are used to treat AK and prevent it from progressing to a more serious form of skin cancer.
Some companies in the Actinic Keratosis Drug market include Galderma, Leo Pharma, and Sun Pharmaceuticals. Show Less Read more